Herein, we demonstrated, for the first time, the enhanced antitumor activity of NK and CIK cells against sarcoma cells pretreated with the trabectedin-olaparib combination, as well as the loss of this efficacy when the cGAS-STING-IRF3-IFNβ pathway is impaired. This evidence concerns the gene IRF3 and sarcoma.